FG Onco 5-Fluorouracil
Pharmacogenetics of 5-fluorouracil (capecitabine) treatment
5-fluorouracil (5-FU) is one of the most used drugs in the treatment of several types of solid tumors: Colorectal cancer, breast cancer, pancreatic cancer, stomach cancer, prostate cancer, head and neck cancer, among others. The major enzymes involved in the response and toxicity to 5-FU and capecitabine are the metabolizing enzyme DPD and the target enzyme TS, which are encoded by the DPYD and TYMS genes, respectively. The DPD enzyme catabolizes approximately 80% of 5-FU, the active metabolite, to an inactive metabolite. D and TYMS, respectively. The DPD enzyme catabolizes approximately 80% of 5-FU, the active metabolite, to an inactive metabolite. Therefore, certain mutations in the DPYD and TYMS genes are responsible for the variable response to treatment and for a significant percentage of the serious adverse reactions to these drugs.
The genetic profile FG – Onco 5-Fluorouracil studies the main allelic variants of the DPYD and TYMS genes with clinical relevance known. The aim of the analysis is to identify those patients with an increased likelihood of developing serious side effects to treatment.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients in whom pharmacological treatments do not show the expected results
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.